Targeted therapy is not suitable for everyone. Only patients with positive results from gene testing or tissue protein testing can receive targeted therapy. For example, in the case of semi colorectal tumors, patients need to carry out tissue K-rad testing, and only the wild type will benefit from it. For example, patients with lung cancer need to undergo EGFR. Mutations are found in patients with EGFR mutations on the surface growth factor receptor, including tyrosine kinase inhibitors and glutamate kinase inhibitors. These oral small molecule preparations are targeted to benefit from drugs. For example, lung cancer also needs to be tested for HER2. That is to say, targeted drugs are different from traditional cytotoxic drugs. It must have a change mutation in a protein tissue or gene sample, and specific drug types can benefit from targeted drugs. This is also the difference between traditional chemotherapy drugs.
